Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

Abstract Introduction Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy. While this drug has been shown to be a safe and e...

Full description

Bibliographic Details
Main Authors: Massimiliano Scalvenzi, Milena Cappello, Claudia Costa, Gabriella Fabbrocini, Mariaantonietta Luciano, Alessia Villani
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-04-01
Series:Dermatology and Therapy
Subjects:
Basal cell carcinoma
Low-dose
Treatment
Vismodegib
Online Access:https://doi.org/10.1007/s13555-020-00371-1

Internet

https://doi.org/10.1007/s13555-020-00371-1

Similar Items